COMPANIES: INDUSTRIES:
Biotechnology Jobs & Careers Search
Find your next job in Biotechnology. Search Biotechnology jobs from thousands of job and career search sites.
A search engine for jobs with a different approach to job and career searches. In one simple search, job
seekers get free access to millions of employment opportunities from thousands of websites. Find your next job in Biotechnology today.
Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide
As global temperatures and energy costs continue to soar, renewable sources of energy will be key to a sustainable future. An attractive replacement for gasoline is biofuel, and in two studies ...
Novartis receives regulatory approval in Germany for cell culture-based Influenza A(H1N1) pandemic vaccine
Novartis announced that it received approval from the German regulatory authorities for its adjuvanted cell culture-based Influenza A(H1N1) 2009 monovalent vaccine, Celtura®. Novartis continues to ...
Catalent expands capabilities in testing for melamine in food and medicinal products
At a time when melamine-contamination has received global attention, Catalent Pharma Solutions continues to rapidly develope new FDA guidance-compliant tests for trace amounts of key contaminants in ...
Hybrid molecules show promise for exploring, treating Alzheimer's
One of the many mysteries of Alzheimer's disease is how protein-like snippets called amyloid-beta peptides, which clump together to form plaques in the brain, may cause cell death, leading to the ...
Monsanto Breaks Ground on Lubbock Cotton Research Facility
To increase yield potential and produce better quality fiber are the goals of Monsanto Company's $10.5 million research "megasite" in Lubbock, where the company broke ground on the site. The megasite ...
Study points to new uses, unexpected side effects of already existing drugs
Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new ...
Singapore scientists join international study of 10,000 vertebrates' genomes
The Singapore laboratory that deciphered the DNA codes, or genomes, of the famed fugu (or pufferfish) and elephant shark, has joined The Genome 10K Project, an international effort to build an ...
Magnetic nanoparticles to simultaneously diagnose, monitor and treat
Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve ...
Quintiles Opens Expanded Asia-Pacific Headquarters in Singapore
To meet the growing demand for its services throughout the Asia-Pacific region, Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and ...
TranScrip Partners appoints David Oxlade as Chairman of the Board
TranScrip Partners LLP, a pharmaceutical development company providing expert advice and hands-on support to pharmaceutical and biotechnology companies across a wide range of therapeutic areas, ...
Deinove receives €6 million in funding from the French state innovation agency OSEO
Deinove, a biotech start-up dedicated to the research and development of processes for biofuel production, announced that it has been awarded €6 million in funding by the French state innovation ...
New Merck begins operations
Merck & Co., Inc. outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation. The new Merck is a global health care leader aimed at providing innovative, ...
Novartis to expand its human vaccines presence in China through proposed acquisition of a majority stake in Zhejiang Tianyuan
Novartis has reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry ...
Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours
Transgene S.A. announced the enrolment of the first patient in the Phase I trial of TG4023 (MVA-FCU1), its newest product to enter clinical trials. Transgene is developing TG4023, a Modified Vaccinia ...
Cipher appoints Dr. William Claypool to Board of Directors
Cipher Pharmaceuticals Inc. (announced that Dr. William Claypool, M.D., has been appointed to its Board of Directors.Since October 2008, Dr. Claypool has been a Senior Partner at Pennmark Associates, ...
Drought-tolerant cowpea can improve crop yield in arid West Africa
Even the highly drought-resistant cowpea (a long type of legume) now has an increasingly difficult time surviving in the Sahel countries where climate change has resulted in shorter and less frequent ...
VisualSonics Appoints New President and CEO
VisualSonics Inc. announced that the Board of Directors has permanently appointed Anil Amlani, as President and Chief Executive Officer of the Company. Mr. Amlani, previously the Chief Financial ...
Monsanto Opens First Biotechnology Research Center in China
Monsanto Company announced that it is opening its first research center in China, further demonstrating its commitment to forming technology collaborations in the country. The Monsanto Biotechnology ...
World's largest malaria vaccine trial now underway in 7 African countries
A pivotal efficacy trial of RTS,S, a clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The ...
Flemish researchers develop revolutionary technology for use in plant breeding
In collaboration with researchers at VIB-UGent and The University of Antwerp (UA), scientists at the BioScience business group of Bayer CropScience AG in Gent have developed a technology that can ...
Bionity.COM News
The latest news about trends and developments in the biotech, pharma and life science industries
How Drug Advertising Restrictions Could Benefit the Industry
BNET -- The drug business spends $5 billion a year on advertising and yet studies continue to emerge suggesting that hundreds of millions of those dollars are wasted. Perhaps its time to consider whether more restrictions on drug ads might, counterintutively, benefit the industry.
Abraxis BioScience, Inc. Opens $70 Million Phoenix Manufacturing Site; Will Create up to 200 Technology Jobs
IMS Health to be Sold for $5.2 Billion, Employs 1,000 in Plymouth Meeting
Quintiles, Inc. Opens Expanded Asia-Pacific Headquarters in Singapore; Potential to More than Double Singapore Workforce
FDA Approves Gloucester Pharmaceuticals, Inc.'s ISTODAX(R) for Patients with Cutaneous T-cell Lymphoma
New Gene Therapy Halts 2 Boys' Rare Brain Disease, Study
Genes Linked to 'Pot' Belly, University of Texas Southwestern Medical Center Study
Dutch Pull Pfizer Inc. Vaccine Batch, Prevenar, After Infants Die
Stanford University Medical Center Study Shows Neural Stem Cells In Mice Affected By Gene Associated With Longevity
Approved Lymphoma Drug Shows Promise In Early Tests Against Bone Cancer, University of Rochester Medical Center Study
Graceway Pharmaceuticals, LLC Acquires Worldwide Rights to GS 9191 from Gilead Sciences, Inc.
Cause Of Common Chronic Diarrhea Revealed In New Research, Imperial College London, King's College London, and University of Edinburgh Study
FDA Approves Labeling Update for Bristol-Myers Squibb Company's REYATAZ(R) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients
Lonza Group Ltd. Buys AlgoNomics
Finding May Help Some Tonsil Cancer Patients Avoid Chemotherapy, Study
Abbott Laboratories Loss to Johnson & Johnson Upheld in $1.7 Billion Patent Suit
RXi Pharmaceuticals Appoints as CEO
Brainwave Sofa Is Exactly What You Were Thinking
Outrage as Doctors' Group Allows Coca-Cola to Sponsor Health Advice
Complete Horse Genome Sequence Revealed, University of California, Davis (UCD) Study
Par Pharmaceutical, Inc. Q3 Profit Beats Estimates on Strong Revenue
TiGenix Says May Raise Capital to Fund Growth
Complete Genomics, Inc. Sequences Whole Human Genome for $1,700
Sleep Apnea Therapy Improves Golf Game, Study
Johnson & Johnson to Close Two Philadelphia Area Sites
Oral Contraceptives May Benefit Women with Asthma, McMaster University Study
Danish Biotech Genmab A/S to Reorganize, to Sell U.S. Plant and Cut 300 Jobs
Folic Acid Supplements Linked To Asthma, Study Suggests
Experimental Vaccine Cures Pre-Cancer Vulvar Growths, Leiden University Medical Center Study
Discovery Laboratories Says to Look for Pipeline Funding
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer; Fails to Meet Secondary Endpoint of Overall Survival
Lung Tissue Generated From Human Embryonic Stem Cells, Vrije Universiteit Brussel Study
Metabolex, Inc. Closes $8.6 Million Financing Round
Merck & Co., Inc. CEO "Actively Looking" for Biotech Deals
GenVec Inc. Cancer Drug Gets Orphan Status
Gene Discovery Gives Clues to Crohn's Disease, Colitis, University College London Study
Zyngenia Raises $10 Million in Series A Funding
Merck & Co., Inc. CEO Plans to Keep Schering-Plough Corporation Headquarters
Cardinal Health, Inc. Posts Net Loss Due to Costs of Spinoff
Biovail Corporation Profit Lower on Restructuring Charges
King Pharmaceuticals??, Inc. Reports Profit Fall
Pfizer Inc. Jury Said to Award $75 Million Prempro Verdict to Woman
Astellas Pharma Inc. Cuts Outlook as Generic Competition Heats Up
New Merck & Co., Inc. Begins Operations Worldwide; Now No. 2 Drugmaker, Set for Future Buys
FDA Won't Accept Merck & Co., Inc.'s Application for New Drug
FDA Approves Nuvo Research Inc., Covidien's Pennsaid(R) Topical Solution
Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. Phase 2 Data of Investigational Drug, Hematide, Suggest Its Ability to Restore Hemoglobin in Patients With Pure Red Cell Aplasia
How Much Egg Sensitivity Makes a Flu Shot Dangerous for Your Child?
Pet Cat in U.S. Catches Swine Flu
Breast Cancer Vaccine Tests German Merck KGaA's $1 Billion Strategy
Biovitrum AB and Swedish Orphan AB Combine to Form
Green Tea Shows Promise As Chemoprevention Agent For Oral Cancer, University of Texas MD Anderson Cancer Center Study Finds
Acetaminophen May Be Linked To Asthma In Children And Adults, University of British Columbia Study
Two Genes Cooperate To Cause Aggressive Leukemia, University of Gothenburg Study
Statins May Worsen Symptoms In Some Cardiac Patients, Northeastern University and Massachusetts General Hospital Study
CARBOGEN AMCIS Announces Company Restructure; 40 Positions Across Swiss Operations to be Lost
ALZA Corporation Faces Layoffs in Vacaville, California
New Activity Found For A Potential Anti-cancer Agent From Marine Sponges, Texas A&M University and Johns Hopkins University Study
Coffee And Nighttime Jobs Don't Mix, University Of Montreal Study Finds
Johnson & Johnson to Cut 7,000-8,000 Jobs in Restructuring
Estrogen And Stroke Risk: Long Period Of Estrogen Deprivation Can Lead To Loss Of Sensitivity And Protective Effects In The Brain, Medical College of Georgia, University of Texas Health Science Center, and Study
University of California, Los Angeles (UCLA) Researchers Reconstitute Enzyme That Synthesizes Cholesterol Drug Lovastatin
Stiefel Laboratories Closing Coral Gables Headquarters; Layoff 40
FDA Grants Priority Review for Shire plc's Velaglucerase Alfa for Type 1 Gaucher Disease; PDUFA Date is February 28, 2010
Student Dissertation Launches San Diego Life Sciences Tools Company, Sirigen Inc.
Cevec Pharma Raises Eur 4 Million
Flamel Technologies Announces Licensing Agreement with Pfizer Inc.
American Regent, Inc. Expands Voluntary Recall to Include All Lots of Ketorolac Tromethamine Injection, USP 15 mg/mL; 1mL Single Dose Vials
Novartis Corporation Buys Stake in China Vaccine Company, for $125 Million
King Pharmaceuticals??, Inc. Sues ZymoGenetics, Inc. Alleging Trademark Violation
Omnicare, Inc., Teva Pharmaceutical Industries Limited Unit Pay $112 Million for Kickbacks
Singapore Roche Plant to Create 100 Jobs
Study Points To New Uses, Unexpected Side Effects Of Already-Existing Drugs, University of North Carolina and University of California, San Francisco (UCSF)
Low Cholesterol May Help Prevent Cancer, National Cancer Institute Study
New GlaxoSmithKline, Pfizer Inc. Company Launches; New Specialist HIV Company Dedicated to Delivering Advances in HIV Treatment and Care
Children Who Often Drink Full-fat Milk Weigh Less, University of Gothenburg Research Finds
Heart Attack Myth: Women Do Have Same The Heart Attack Symptoms As Men, Canadian Institutes Of Health Research Study Shows
Common Pain Relievers May Dilute Power Of Flu Shots, University of Rochester Medical Center Study
Richard P. Phipps, Ph.D., professor of Environmental... Hemispherx Biopharma Responding to FDA's Ampligen Questions
Drug Company-sponsored Events For Health Professionals Fail To Disclose Financial Ties, Analysis Finds
New Genetic Cause Of A Fatal Immune Disorder, Research
Certain Antibiotics May Up Birth Defect Risk, Centers for Disease Control and Prevention (CDC) Study
Nicotine Patch Plus Lozenge Best for Quitting Smoking, National Institutes of Health (NIH) Funded Study
Processed Food Increases Depression Risk, University College London Study
FDA Denies Approval for GTx, Inc. Drug; Seeks Additional Study
Novartis International AG to Invest $1 Billion in China
Developmental Drug May Help Bone Fractures Heal After Radiation Exposure, University of Pittsburgh School of Medicine Study
Ironwood and Forest Laboratories, Inc. Announce Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation; Top-line Results Show Each Trial Met Primary and All Secondary Endpoints
Eli Lilly and Company Reducing Sales Force By 191 as Part of Larger Restructuring
Osiris Therapeutics, Inc. Achieves $15 Million Milestone Payment from NuVasive, Inc.
Quintiles, Inc. Inks Pharma Deal with AstraZeneca PLC
Possible Origins Of Pancreatic Cancer Revealed by Massachusetts Institute of Technology (MIT) Biologists
World's Largest Malaria Vaccine Trial Now Underway In 7 African Countries, GlaxoSmithKline Biologicals Study
Verenium Corporation and Close Research Collaboration; Portfolio of Development Candidates Strategically Divided Between Companies
Takeda Pharmaceuticals North America, Inc. Establishes Expanding Presence in North America
US FDA Issues Alert on Kidney Problems with Eli Lilly and Company , Amylin Pharmaceuticals, Inc.'s Byetta
U.S. Seeks More Information on MDS Analytical Technologies-Danaher Deal
Bristol-Myers Squibb Company, Sanofi-Aventis (France) Prevail in Fight Over Plavix
West Pharmaceutical Services Q3 Lags Estimates, to Cut 100 Jobs
Merck & Co., Inc. and Schering-Plough Corporation to Complete Merger Today; New Will Begin Combined Operations Tomorrow
XOMA (US) LLC Signs Antibody Discovery Collaboration With Kaketsuken; to Get $8 Million
Speed Limit To The Pace Of Evolution, University of Pennsylvania Biologists Say
Pancreatic Cancer: Discovery Offers Potential New Treatment, Ohio State University Study
Iowa State University Researchers' Findings Bring Hope for Possible Parkinson's Disease Cure
Vision of the Future: Custom Corneas
Anemia Drug May Raise Stroke Risk in Kidney Patients, Brigham and Women's Hospital Study
Amylin Pharmaceuticals, Inc. Strikes $1 Billion Deal with Takeda Pharmaceutical Co. Ltd. to Co-Develop Weight Loss Drugs
First Draft of the Pig: Researchers Sequence Swine Genome, University of Illinois Study
Next-generation Microcapsules Deliver 'Chemicals On Demand', University of California, Berkeley (CAL) and Lawrence Berkeley National Laboratory Research
Can Charcoal Fight Heart Disease In Kidney Patients?
Unexpected Consequences Of Proton Pump Inhibitor Use In Reflux Disease
Perrigo Company Divests Israel Business for 205 Million New Israeli Shekels (US $54 Million)
Genetic Links To Fungal Infection Risk Identified, University College London and Study
Amylin Pharmaceuticals, Inc. Says Byetta Gets FDA Approval for New Use
Pfizer Inc. Eyes Deal with Israel's Protalix Biotherapeutics
Alternatively Spliced Tissue Factor Identified As Promising New Biomarker For Aggressive Cancers, University of Cincinnati and Leiden University Medical Center Study
FDA Concerns Remain Over New Use for Schering-Plough Corporation Drug, PegIntron
Human Genome Sciences, Inc. , GlaxoSmithKline Lupus Drug Works in 2nd Trial
Eisai Inc. : Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
WOODCLIFF LAKE, N.J., Oct. 30 /PRNewswire/ -- Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer. This global Phase III study, known as "EMBRACE," (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice... Switching Immunosuppressants Reduces Cancer Risk In Kidney, Queen Elizabeth Hospital Study
Extending Treatment After Liver Transplant May Benefit Patients With Hepatitis C Recurrence, Henry Ford Hospital Study
LFB Biotechnologies Provides $10 Million of Funding To GTC Biotherapeutics
Pulmatrix Closes $30.2 Million in Series B Financing
Cequent Pharmaceuticals, Inc. Closes Tranche of $10.8 Million Round
Bellicum Pharmaceuticals, Inc. Raises $4.5 Million
Abraxis BioScience, Inc. Opens $70 Million Phoenix Manufacturing Site; Will Create up to 200 Technology Jobs
IMS Health to be Sold for $5.2 Billion, Employs 1,000 in Plymouth Meeting
Quintiles, Inc. Opens Expanded Asia-Pacific Headquarters in Singapore; Potential to More than Double Singapore Workforce
FDA Approves Gloucester Pharmaceuticals, Inc.'s ISTODAX(R) for Patients with Cutaneous T-cell Lymphoma
Dutch Pull Pfizer Inc. Vaccine Batch, Prevenar, After Infants Die
Graceway Pharmaceuticals, LLC Acquires Worldwide Rights to GS 9191 from Gilead Sciences, Inc.
FDA Approves Labeling Update for Bristol-Myers Squibb Company's REYATAZ(R) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients
Lonza Group Ltd. Buys AlgoNomics
Abbott Laboratories Loss to Johnson & Johnson Upheld in $1.7 Billion Patent Suit
RXi Pharmaceuticals Appoints as CEO
Par Pharmaceutical, Inc. Q3 Profit Beats Estimates on Strong Revenue
TiGenix Says May Raise Capital to Fund Growth
Complete Genomics, Inc. Sequences Whole Human Genome for $1,700
ZIOPHARM Oncology, Inc. Presents Positive Palifosfamide Sarcoma Randomized Phase II Interim Data at Annual Meeting of the
Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
PARIS, November 6 /PRNewswire/ -- - Trial Will Compare NXL103 With Leading Oral Agent Linezolid for the Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that... Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at Annual Meeting
CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled... Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
HAYWARD, Calif., Nov. 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS(R) continuous delivery of exenatide) program for the treatment of type 2 diabetes at the Ninth Annual Diabetes Technology Meeting in San Francisco, CA: Continuous Subcutaneous Delivery of Exenatide Via ITCA 650 Lowers Plasma Glucose, HbA... Threshold Pharmaceuticals, Inc. Presents Interim Data From a Phase 1/2 Clinical Trial of TH-302 at Sarcoma Meeting
XOMA (US) LLC Expands Development Strategy for XOMA 052 to Include Cardiovascular Diseases
Genetix Pharmaceuticals, Inc. Announces Global Clinical Plans to Treat Adrenoleukodystrophy (ALD)
Puredel Limited Release: Ossulin(TM) Oral Insulin Data to be Presented at The San Francisco Diabetes Congress on November 6, 2009
Chimerix, Inc. Updates the World Health Organization and the on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
RESEARCH TRIANGLE PARK, N.C., Nov. 6 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, presented updates on the development of the company's lead antiviral compound, CMX001, to the World Health Organization (WHO) and the Global Health Security Initiative (GHSI). CMX001 is a broad-spectrum antiviral... NexBio, Inc. Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
SAN DIEGO, Nov. 6 /PRNewswire/ -- NexBio Inc., in collaboration with scientists at the Centers for Disease Control and Prevention (CDC), St. Louis University, and the University of Hong Kong, announced today the publication of two articles in the peer-reviewed journal PLoS ONE. These two published studies suggest that DAS181 (Fludase(R)) may play a potentially important role for the treatment... EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus
VIENNA, Austria, November 6 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry announced today that it has entered into a research agreement with Bio Sidus, the leading biopharmaceutical company in Latin America. The agreement gives EUCODIS Bioscience exclusive access - for the search of enzymes of interest... PPD, Inc. Completes Acquisition of
RiskMetrics Recommends Stockholders Vote ???FOR??? Life Sciences Research, Inc./Merger
Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus
SPRING VALLEY, Calif., Nov. 6 /PRNewswire/ -- Calbiotech, Inc. announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the U.S. Army Medical Research and Material command. Under terms of the agreement, Calbiotech will develop analyte specific reagents (ASRs) for the diagnosis of Dengue virus. Technology developed... Theravance, Inc. and Astellas Pharma Inc. Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
SOUTH SAN FRANCISCO, CA and DEERFIELD, IL--(Marketwire - November 05, 2009) - Theravance, Inc.(NASDAQ:
BioMarin Pharmaceutical Inc.: United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food
NOVATO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. announced today that the United States Patent and Trademark Office has issued a patent covering the approved administration of Kuvan(R) (sapropterin dihydrochloride) with food for the treatment of phenylketonuria (PKU). The patent expires in 2024. About Kuvan Kuvan has received... Biostar Pharmaceuticals, Inc. Announces Closing of a $3.6 Million Equity Financing
Delisting of Securities of Hana Biosciences, Inc. From The Stock Market
Locus Pharmaceuticals, Inc. Announces Focus on Drug Discovery Collaboration Business,
Althea Technologies, Inc. Adds Formulation Development to Its Integrated Offering of Contract Services
SAN DIEGO, Nov. 5 /PRNewswire/ -- Althea Technologies, Inc., a leading provider of development and manufacturing services for biopharmaceutical products announced the addition of customized Formulation Development to the company's platform of services, which will be overseen by the newly appointed Dr. James Matsuura, Director of Formulation Development. This investment in an experienced... Achillion Pharmaceuticals, Inc. Reports Third Quarter Results
Aceto Corporation Announces Fiscal 2010 First Quarter Results of Operations
Athersys, Inc. Reports 2009 Third Quarter Results
Alkermes Reports Second Quarter Fiscal 2010 Financial Results
Sucampo Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of 2009
Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2009
Ardea Biosciences, Inc. Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), today reported recent accomplishments and financial results for the third quarter and nine months ended September 30, 2009. (Logo: http://www.newscom.com/cgi... Aastrom Biosciences, Inc. Reports First Quarter Fiscal Year 2010 Financial Results
BioSpecifics Technologies Corporation Reports Third Quarter 2009 Financial Results
LYNBROOK, N.Y., Nov. 5 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. , a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009. "We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously recommended, by a vote of... BioMimetic Therapeutics, Inc. Reports 2009 Third Quarter Earnings Results
Bioniche Pharma Ltd. Reports Fiscal 2010 First Quarter Results And Achievement of First Milestone Under Licensing Agreement
BELLEVILLE, ON, Nov. 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. , a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009. "We ended the first quarter of Fiscal 2010 in a strong position, with current assets of $25.3 million, 53% of which is cash," stated... BIOLASE Technology, Inc. Reports Third Quarter, Nine-Month Results
IRVINE, CA--(Marketwire - November 05, 2009) - BIOLASE Technology, Inc. (NASDAQ: BLTI), theworld's leading dental laser company, today reported operating results forthe 2009 third quarter and nine months ended September 30, 2009. Net revenue for the third quarter of 2009 was $12.1 million, compared...
Cadence Pharmaceuticals, Inc. Reports Third Quarter 2009 Financial Results
SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. , a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and nine months ended September 30, 2009. Financial Results For the three months ended... BioNovo, Inc. Announces Third Quarter 2009 Highlights and Financial Results
EMERYVILLE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Bionovo, Inc. , a drug discovery and development company focused on the unmet needs in women's health and oncology, today announced third quarter highlights and financial results for the three months ended September 30, 2009. Subsequent to the end of the quarter, in October 2009, Bionovo successfully completed a public offering and... Celsion Corporation to Hold Third Quarter 2009 Financial Results Conference Call Tuesday, November 10, 2009
DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results Q3 Domestic PDT
WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(R) , a dermatology company that is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the third quarter ended September 30, 2009. Third quarter and year-to-date... Evotec AG to Report Third Quarter 2009 Results on 12 November 2009
GTC Biotherapeutics Reports Third Quarter 2009 Financial Results
GenVec Inc. Reports Third Quarter 2009 Financial Results
GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. today announced its financial results for the third quarter ended September 30, 2009. GenVec reported a net loss of $3.6 million ($0.04 per share) for the three months ended September 30, 2009 compared to a net loss of $6.8 million ($0.08 per share) in the comparable quarter of 2008. For the nine months ended September 30, 2009, GenVec... GeoVax Labs Inc. Provides Third Quarter 2009 Financial Results and Operational Update
ATLANTA, Nov. 6 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. ("GeoVax" or "the Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update. Robert McNally, Ph.D., President and Chief... Halozyme Therapeutics, Inc. Reports Third Quarter 2009 Financial Results
Immunomedics, Inc. Announces First Quarter Fiscal 2010 Results and Clinical Program Developments
Helix BioMedix, Inc. Reports Third Quarter 2009 Financial Results
Inhibitex, Inc. Reports Third Quarter 2009 Financial Results
InterMune, Inc. Reports Third Quarter 2009 Financial Results and Business Highlights
BRISBANE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced results from operations for the third quarter and nine months ended September 30, 2009. InterMune reported a net loss for the third quarter of 2009 of $8.8 million, or $0.19 per share, compared with a net loss of $14.0 million, or $0.36 per share, in the third quarter of 2008. Dan Welch, Chairman, Chief... Insmed Incorporated Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009
RICHMOND, Va., Nov. 6 /PRNewswire-FirstCall/ -- Insmed Inc. , a biopharmaceutical company, today reported results for the third quarter and nine-months ended September 30, 2009. The net loss for the third quarter of 2009 was $150,000; break even on a dollar per share basis, compared with a net loss of $2.2 million, or $0.02 per share, in the third quarter of 2008. This... Jazz Pharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results -Achieved Record Quarterly Net Product Sales of $30 Million - Raising Revenue Guidance for 2009
PALO ALTO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. today announced financial results for the third quarter ended September 30, 2009. "Our sales team delivered another solid quarter for us with record numbers of XYREM and LUVOX CR prescriptions and net sales" said Bob Myers, President of Jazz Pharmaceuticals. Jazz... Ligand Pharmaceuticals Inc. Announces Third Quarter Results
Labopharm Reports Results for Third Quarter Fiscal 2009
LAVAL, QC, Nov. 6 /PRNewswire-FirstCall/ - Labopharm Inc. today reported its financial results for the third quarter ended September 30, 2009. All figures are in Canadian dollars unless otherwise stated. "We have made strong progress in recent months towards the commercialization of our novel trazodone formulation in both the United States and Canada," said James R. Howard... Life Sciences Research, Inc. Announces Third Quarter Results
Maxygen, Inc. Reports Third Quarter 2009 Financial Results
Nabi Biopharmaceuticals Announces Third Quarter 2009 Financial Results
Neurogen Corporation Announces Third Quarter 2009 Financial Results and Updates Operations
Novavax, Inc. Reports Third Quarter 2009 Financial Results
ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. today announced financial results for the third quarter ended September 30, 2009 and reviewed its recent accomplishments and upcoming milestones. Novavax's net loss for the third quarter of 2009 was $7.5 million, or $0.08 per share, compared to a net loss of $7.8 million, or $0.12 per share, for the same period last year... NeurogesX, Inc. Reports Third Quarter 2009 Results Conference Call Today at 9am ET
SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- 3Q09 Corporate Highlights: Upcoming 2009 Milestones: NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the third quarter ended September 30, 2009. During the third quarter of 2009, NeurogesX... Novadaq Corp. Expands Q3-09 Financial Results Conference Call to Include Live Webcast
TORONTO, ONTARIO--(Marketwire - November 05, 2009) - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for the operating room, announced today that it is expanding the scope of its Q3-2009 financial results conference call, scheduled for November 12, 2009 at 1...
Osteotech, Inc. Reports Third Quarter 2009 Financial Results Company Achieves Sequential and Year-Over-Year U.S. Sales Growth In Base Business 2009 Guidance Updated Call on November 6, 2009 at 9:00 a.m. EST
EATONTOWN, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Osteotech, Inc. , a leader in the emerging field of biologic products for regenerative healing, today reported financial results for the third quarter ended September 30, 2009. "During the third quarter of 2009, our focus was on the release of our three new biologic products MagniFuse(TM) Bone Graft, FacetLinx(TM) Fusion Technology... OncoGenex Pharmaceuticals Inc. Reports Third Quarter 2009 Financial Results
Conference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time BOTHELL, WA and VANCOUVER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") today reported unaudited financial results for the third quarter and nine months ended September 30, 2009 and reviewed the Company's highlights for the third quarter of 2009. The following... Par Pharmaceutical, Inc. Reports EPS of $0.76 for Third Quarter 2009 Achieves Record Quarterly Gross Margin of $92 Million
WOODCLIFF LAKE, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today reported results for the third quarter ended October 3, 2009. For the third quarter ended October 3, 2009, Par reported total revenues of $294.8 million and net income of $26.3 million, or $0.76 per diluted share. This is compared to reported revenues of $149.0 million and net income of... Spectrum Pharmaceuticals, Inc. Announces Date for Third Quarter 2009 Corporate Update and Pipeline Review Conference Call
Somaxon Pharmaceuticals, Inc. Reports 2009 Third Quarter Financial Results
Stellar Pharmaceuticals Inc.'s Q3-2009 Financial Results Marked by Strong Growth and Continued Profitability
LONDON, ONTARIO--(Marketwire - November 06, 2009) - Stellar Pharmaceuticals Inc. ("Stellar" or "the Company") (OTCBB: SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced its financial results for the third quarter...
Threshold Pharmaceuticals, Inc. Reports Third Quarter 2009 Financial Results
Transcept Pharmaceuticals, Inc. to Report Third Quarter 2009 Results and Host Conference Call on November 12
POINT RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it will host a webcast and teleconference with management to discuss third quarter 2009 financial results... Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2009 Financial Results
SEATTLE, Nov. 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. today announced financial results for its third quarter and nine months ended Sept. 30, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) Third Quarter and Nine Months 2009 Financial Results Revenue for the third quarter and nine months ended Sept. 30, 2009, was $4.5 million... Targacept, Inc. Reports Third Quarter 2009 Financial Results
ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
RANCHO CORDOVA, Calif., Nov. 5 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. , a leading supplier of innovative products for processing and storing adult stem cells, today reported results for the first quarter of fiscal 2010. For the quarter ended September 30, 2009, the Company reported revenues of $5.2 million, a 15 percent increase over revenues of $4.5 million in the first quarter... ZymoGenetics, Inc. Reports Third Quarter 2009 Financial Results
Amarin Corporation PLC Appoints as Chief Financial Officer
TARIS Biomedical Appoints to CMO Post
EpiCept Corporation Names as Senior Vice President, Sales and Marketing
Emisphere Technologies, Inc. Appoints to the Board of Directors
Washington Biotechnology & Biomedical Association???s New ???Healthcare Economics in WA??? Breaking News is Powered by
Purdue Research Foundation to Recognize 32 Faculty and Staff Entrepreneurs, Inventors
Phase Forward Named Private Sector Company of the Year by
Laboratory Corporation of America Holdings (LabCorp) is Scheduled to Present at the 18th Annual Healthcare Conference
Sucampo Pharmaceuticals, Inc. Invites Investors to Listen to Webcast of Presentation at Conference
Amylin Pharmaceuticals, Inc. to Present at the 18th Annual Healthcare Conference
SAN DIEGO, Nov. 5, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will be presenting at the 18th Annual Credit Suisse Healthcare Conference in Phoenix, Arizona on Wednesday, November 11, 2009 at 10:00 a.m. PT / 1:00 p.m. ET. Mark Foletta, senior vice president of finance and chief financial officer at Amylin Pharmaceuticals, will be providing a corporate overview. <... BioScrip to Present at 18th Annual Healthcare Conference
King Pharmaceuticals??, Inc. to Present at Healthcare Conference
Johnson & Johnson to Close Two Philadelphia Area Sites
Danish Biotech Genmab A/S to Reorganize, to Sell U.S. Plant and Cut 300 Jobs
AP -- French scientists mixed gene therapy and bone marrow transplants in two boys to seemingly halt a brain disease that can kill by adolescence. The surprise ingredient: They disabled the HIV virus so it couldn't cause AIDS, and then used it to carry in the healthy new gene. The experiment marks the first time researchers have tried that long-contemplated step in people and the first effective...
HealthDay News -- New research sheds light on the possible link between the genes you inherit and the size of your belly.
EurekAlert -- A gene associated with longevity in roundworms and humans has been shown to affect the function of stem cells that generate new neurons in the adult brain, according to researchers at the Stanford University School of Medicine. The study in mice suggests that the gene may play an important role in maintaining cognitive function during aging.
EurekAlert -- A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. The study drug, Bortezomib, was found to be effective against bone cancer in human cancer cell studies and in mice. While key experiments were in animals, the...
ScienceDaily (Nov. 6, 2009) A common type of chronic diarrhea may be caused by a hormone deficiency, according to new research published in the November issue of Clinical Gastroenterology and Hepatology. The authors of the paper, from Imperial College London, with collaborators from King's College London and the University of Edinburgh, say their results could help more doctors recognise this type...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) today announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for REYATAZ to include long-term data from the CASTLE Study. The CASTLE Study assessed a once-daily REYATAZ/ritonavir (REYATAZ/r)-based regimen versus a twice-daily lopinavir/ritonavir (LPV/r)-based regimen in previously untreated...
ScienceDaily (Nov. 6, 2009) Clinical researchers at Princess Margaret Hospital (PMH) have confirmed that patients with oropharyngeal squamous cell cancer ("tonsil cancer") harbour a common type of human papilloma virus (HPV16), but also that such cancers are very sensitive to radiation. For some patients, this may mean successful treatment with radiation alone and avoiding the side effects of chemotherapy...
medGadget -- Ever wondered what a piece of furniture formed from raw data extracted from your brain would look like? But of course you have, and so did Lucas Maassen and Dries Verbruggen, the designers of the Brainwave Sofa.
Advice about soft drinks and health from one of the nation's largest doctors groups will soon be brought to you by Coke.The American Academy of Family Physicians has prompted outcry and lost members over its new six-figure alliance with the Coca-Cola Co. The deal will fund educational materials about soft drinks for the academy's consumer health and wellness Web site, www.FamilyDoctor.org.
HealthDay News -- The genome of the domestic horse has been sequenced, an accomplishment that will improve the breeding of horses and may help studies of human health, according to an international team of researchers.
Men Find New Motivation for Using CPAP
SAN DIEGO, Nov. 2 /PRNewswire-USNewswire/ -- Golfers who undergo treatment forsleep apnea may improve their golf game as well as their overall health, showsnew research. A new study presented at CHEST 2009, the 75th annualinternational scientific assembly of the American College of Chest Physicians(ACCP), found that golfers with obstructive...
Philly.com -- Johnson & Johnson said today that it was closing research & development facilities in Radnor and Chesterbrook and consolidating those operations at the company's Spring House site.
EurekAlert -- New research shows that during natural menstrual cycles, women with asthma who were not taking oral contraceptives (OC) had lower exhaled nitric oxide levels (eNO), a marker of airway inflammation associated with asthma, than women who were taking OC. Researchers from McMaster University in Hamilton, ON, Canada, studied 17 women with asthma during their menstrual cycles. Results showed...
ScienceDaily (Nov. 4, 2009) A University of Adelaide study may have shed light on the rise in childhood asthma in developed countries like Australia in recent decades. Researchers from the University's Robinson Institute have identified a link between folic acid supplements taken in late pregnancy and allergic asthma in children aged between 3 and 5 years, suggesting that the timing of supplementation...
Reuters - An experimental vaccine cured nearly half of women with pre-cancerous growths on their genitals, producing major improvement in nearly four out of five, researchers in the Netherlands reported on Wednesday.
ScienceDaily (Nov. 5, 2009) Scientists in Belgium have successfully differentiated human embryonic stem cells (hESC) into major cell types of lung epithelial tissue using a convenient air-liquid interface. The technique, published in BioMed Central's open access journal Respiratory Research, could provide an alternative to lung transplants for patients with lung injury due to chronic pulmonary disease...
MedPage Today -- Genetic mutations in interleukin-10 receptors may be responsible for inflammatory bowel disease in patients who inherit the disorder, researchers said. In an analysis of two children who had early onset of the disease and their families, the researchers found mutations in genes encoding the IL10R proteins, which make up interleukin-10 receptors, according to Erik-Oliver Glocker, MD...
Bloomberg -- Merck & Co. Chief Executive Officer Richard T. Clark said he plans to keep Schering-Plough Corp.s headquarters after completing the acquisition of the company.
Bloomberg -- Pfizer Inc. must pay about $75 million in punitive damages to an Illinois woman who developed cancer after taking one of the drugmakers menopause treatments, people familiar with a sealed verdict in the case said.
PALO ALTO, Calif., & DEERFIELD, Ill.--(Business Wire)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research &Development Center, Inc., today announced data from a Phase 2 clinical trial ofHematide showing that Hematide increased hemoglobin and reduced or eliminatedthe need for blood transfusion in most patients with erythropoietin-induced purered cell aplasia (PRCA). The...
Newswise My three year old had a skin breakout we think was due to eggs is it safe to do a flu shot? Its a question being asked to every doctor who takes care of kids during flu season. On the one hand we are concerned about the devastating effects of the new strain of flu, and on the other we arent sure if a history of eggs sensitivity is enough to hold the shot or spray, said Bobby Q. Lanier...
Reuters A cat in Iowa has tested positive for H1N1 swine flu, the first time a cat has been diagnosed with the new pandemic strain, the American Veterinary Medical Association said on Wednesday. The 13-year-old cat apparently caught the virus from one of the people living in the house, the group said in a statement. It has recovered and does not appear to have infected anyone or anything else....
EurekAlert -- Green tea extract has shown promise as cancer prevention agent for oral cancer in patients with a pre-malignant condition known as oral leukoplakia, according to researchers at The University of Texas M. D. Anderson Cancer Center. The study, published online in Cancer Prevention Research, is the first to examine green tea as a chemopreventative agent in this high-risk patient population...
EurekAlert -- New research shows that the widely used pain reliever acetaminophen may be associated with an increased risk of asthma and wheezing in both children and adults exposed to the drug. Researchers from the University of British Columbia, Vancouver, BC, Canada, conducted a systematic review and metaanalysis of 19 clinical studies (total subjects425,140) that compared the risk of asthma or...
EurekAlert -- Two genes, each one of which is known to cause cancer on its own, together can lead to aggressive leukaemia. This is the conclusion from new research carried out on gene-modified mice at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery has surprised scientists, and may lead to new treatments.
EurekAlert -- Although statins are widely used to prevent heart attacks, strokes, and other cardiovascular disorders, new research shows that the class of drugs may actually have negative effects on some cardiac patients. A new study presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that statins have beneficial effects...
BUBENDORF, Switzerland -- CARBOGEN AMCIS announced its intention to restructure its Swiss operations. The early phase services, currently provided by its facilities in canton Aargau, will be consolidated at the Aarau site. The Hunzenschwil site will focus on new technologies, such as micro-reactors, crystallisation and the using the unique assets of the site. In addition, the late phase and high...
ScienceDaily (Nov. 3, 2009) Pateamine A (PatA), a natural product first isolated from marine sponges, has attracted considerable attention as a potential anti-cancer agent, and now a new activity has been found for it, which may reveal yet another anti-cancer mechanism. That's the assessment of Daniel Romo, a Texas A&M chemistry professor, and his colleagues at Johns Hopkins University who are pioneers...
ScienceDaily (Nov. 4, 2009) Night-shift workers should avoid drinking coffee if they wish to improve their sleep, according to research published in the journal Sleep Medicine. A new study led by Julie Carrier, a Universit de Montral psychology professor and a researcher at the affiliated Hpital du Sacr-Cur Sleep Disorders Centre, has found the main byproduct of coffee, caffeine, interferes...
ScienceDaily (Nov. 4, 2009) Eighteen years ago this month the National Institutes of Health (NIH) announced that it would sponsor a landmark study to examine women and cardiovascular disease. Known as the Women's Health Initiative (WHI), the study enrolled more than 161,000 women. By 2004 however, the government had ended two arms of the study involving estrogen after researchers found it posed a...
EurekAlert -- Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin.
UNC -- Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new target diseases for existing drugs. The researchers developed a computational method that compares how similar the structures of all known drugs are to the naturally occurring binding partners -- known...
HealthDay News -- Low blood cholesterol levels reduce the risk not only of heart disease but also of cancer, two new studies show. The findings should help ease longstanding fears that low cholesterol is associated with an increased risk of cancer, said Dr. Demetrius Albanes, a senior investigator at the U.S. National Cancer Institute, and an author of one of two reports in the November issue of Cancer...
ScienceDaily (Nov. 4, 2009) Eight-year-old children who drink full-fat milk every day have a lower BMI than those who seldom drink milk. This is not the case for children who often drink medium-fat or low-fat milk. This is one conclusion of a thesis presented at the Sahlgrenska Academy.
ScienceDaily (Nov. 3, 2009) The gender difference between men and women is a lot smaller than we've been led to believe when it comes to heart attack symptoms, according to a new study presented to the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.
ROCHESTER, N.Y., Nov. 3 /PRNewswire-USNewswire/ -- With flu vaccination seasonin full swing, research from the University of Rochester Medical Centercautions that use of many common pain killers -- Advil, Tylenol, aspirin -- atthe time of injection may blunt the effect of the shot and have a negativeeffect on the immune system.
ScienceDaily -- ScienceDaily (Nov. 3, 2009) Australian reporting standards for disclosing the ties between pharmaceutical companies and health professionals are not comprehensive enough, according to an analysis in this week's PLoS Medicine.
EurekAlert -- Familial hemophagocytic lymphohistiocytosis (FHL) is an inherited, fatal, immune disorder characterized by uncontrolled activation of immune cells known as lymphocytes and macrophages. Disease-causing mutations have been identified in several genes that generate proteins involved in lymphocyte-mediated cell death, including syntaxin-11. Now, Genevive de Saint Basile and colleagues, at...
ScienceDaily (Nov. 3, 2009) Penicillin and several other antibacterial medications commonly taken by pregnant women do not appear to be associated with many birth defects, according to a report in the November issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals. However, other antibiotics, such as sulfonamides and nitrofurantoins, may be associated with several...
WebMD -- Smokers who want to kick the habit are more likely to succeed when they use a combination of long-acting and immediate-delivery nicotine-replacement products, a study shows. Study participants who used nicotine patches plus nicotine lozenges were more successful than participants who used either product alone. They also had better outcomes than those who used the smoking-cessation drug Zyban...
UPI -- Eating a lot of processed food may increase a person's risk for depression, researchers in Britain found. Tasnime N. Akbaraly, Eric J. Brunner, Jane E. Ferrie, Michael G. Marmot and Mika Kivimak of the University College London analyzed data from 3,486 participants -- 26.2 percent women, mean age 55.6 years -- from the Whitehall II prospective study. Two dietary patterns were identified in the...
ScienceDaily (Nov. 3, 2009) A drug currently under development by the University of Pittsburgh School of Medicine may help bone fractures heal more quickly after radiation exposure, according to a study by Pitt researchers.
EurekAlert -- Study results: MIT cancer biologists have identified a subpopulation of cells that can give rise to pancreatic cancer. They also found that tumors can form in other, more mature pancreatic cell types, but only when they are injured or inflamed, suggesting that pancreatic cancer can arise from different types of cells depending on the circumstances.
EurekAlert -- A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers announced Tuesday at the 5th Multilateral...
ScienceDaily (Nov. 3, 2009) Researchers at the University of Pennsylvania have developed a theoretical model that informs the understanding of evolution and determines how quickly an organism will evolve using a catalogue of "evolutionary speed limits." The model provides quantitative predictions for the speed of evolution on various "fitness landscapes," the dynamic and varied conditions under which...
ScienceDaily (Nov. 3, 2009) Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard...
ISU -- Researchers at Iowa State University have found an essential key to possibly cure Parkinson's disease and are looking for others. Anumantha Kanthasamy, a distinguished professor of biomedical sciences and W. Eugene and Linda R. Lloyd Endowed Chair in Neurotoxicology at the ISU College of Veterinary Medicine, has been working to understand the complex mechanisms of the disease for more than...
Discovery -- NASA technology that allows the Hubble telescope to focus on distant stars now offers LASIK eye surgery patients customized options for fine-tuned night vision, superior image contrast and sight even beyond 20/20.
San Diego Union Tribune -- A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick enough to need dialysis.
EurekAlert -- A global collaborative has produced a first draft of the genome of a domesticated pig, an achievement that will lead to insights in agriculture, medicine, conservation and evolution. A red-haired Duroc pig from a farm at the University of Illinois will now be among the growing list of domesticated animals that have had their genomes sequenced. Researchers will announce the achievement...
ScienceDaily (Nov. 2, 2009) Scientists in California are reporting development of a new generation of the microcapsules used in carbon-free copy paper, in which capsules burst and release ink with pressure from a pen. The new microcapsules burst when exposed to light, releasing their contents in ways that could have wide-ranging commercial uses from home and personal care to medicine.
ScienceDaily (Oct. 31, 2009) Charcoal may provide a new approach to managing the high rate of heart disease in patients with advanced kidney disease, according to preliminary research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.
Medical News Today -- Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed proton pump inhibitors (PPIs) for reflux diseases. Physicians are warned to monitor these effects and prescribe these medications carefully, according to a new commentary published in the November 2009 issue of Otolaryngology -Head and Neck Surgery...
EurekAlert -- Two genetic mutations that may put individuals at increased risk of fungal infections have been identified by scientists from UCL and Radboud University, increasing understanding about the genetic basis of these infections and potentially aiding the development of new treatments. The two separate studies, published today in the New England Journal of Medicine, mark a significant step...
ScienceDaily (Nov. 1, 2009) A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists.
ScienceDaily (Oct. 31, 2009) Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.
Henry Ford Health -- Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study.
Boston Business Journal -- Cambridge-based biotechnology company Cequent Pharmaceuticals has raised $2.7 million of a planned $10.8 million financing round. The funding included investments from Wellesley, Mass.-based Ampersand Ventures, New England Capital Partners in Newton, Mass., and Durham, N.C.-based A.M. Pappas Life Science Ventures.
pehub.com -- Bellicum Pharmaceuticals Inc., a Houston-based drug startup focused on prostate cancer, has raised $4.5 million in Series A and convertible note financing. The company has now raised a total of $8.5 million, including $1.45 million from the Texas Emerging Technology Fund.
BioSpace.com Featured News and Stories
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) today announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for REYATAZ to include long-term data from the CASTLE Study. The CASTLE Study assessed a once-daily REYATAZ/ritonavir (REYATAZ/r)-based regimen versus a twice-daily lopinavir/ritonavir (LPV/r)-based regimen in previously untreated...
NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. As previously announced, having achieved the study-specified efficacy milestone...
REDWOOD CITY, Calif., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting taking place in Miami Beach, Florida from November 5 to 7, 2009.
BERKELEY, Calif., Nov. 6, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the expansion of its development strategy for its XOMA 052 antibody to interleukin-1 beta (IL-1 beta) to include effects on cholesterol lowering, reducing plaque deposits and damage to heart muscle and resulting long-term effects that can lead to...
CAMBRIGE, Mass.--(BUSINESS WIRE)--Genetix Pharmaceuticals, a leader in gene therapy of somatic stem cells, announced today the companys clinical program to treat Adrenoleukodystrophy (ALD). The company is developing a gene therapy product in collaboration with Professor Patrick Aubourg and Doctor Nathalie Cartier of the National Institute of Health and Medical Research (INSERM). Genetix is planning...
LONDON--(BUSINESS WIRE)--The first public data on Ossulin a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited (www.cmdpharmaltd.com) and Natreon Inc., New Brunswick, NJ., developers of the proprietary...
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPDI) today announced it has completed its acquisition of Excel PharmaStudies, Inc., the market leader and one of the largest contract research organizations in China. The acquisition strengthens PPDs full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia...
EAST MILLSTONE, N.J.--(BUSINESS WIRE)--Life Sciences Research, Inc. (NYSE Arca: LSR) announced today that RiskMetrics Group (formerly Institutional Shareholder Services), a leading proxy advisory firm, has recommended that LSR stockholders vote FOR the approval of the merger of LSR and Lion Merger Corp. pursuant to the Agreement and Plan of Merger, dated as of July 8, 2009, among LSR, Lion Merger...
NEW YORK, Nov. 5, 2009 (GLOBE NEWSWIRE) -- The NASDAQ Stock Market announced today that it will delist the common stock of Hana Biosciences, Inc. Hana Biosciences, Inc.'s stock was suspended on September 10, 2009 and has not traded on NASDAQ since that time. NASDAQ will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting becomes effective ten days after...
BLUE BELL, Pa.--(BUSINESS WIRE)--Locus Pharmaceuticals, a drug company that has developed its own internal and partnered pipeline, focusing on oncology, immunology, and inflammatory targets, today announced that in conjunction with a transformation to a drug discovery collaboration business model, it has created a new division, Ansaris, which will include most of its operations and personnel. Ansaris...
NEW HAVEN, Conn., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and nine months ended September 30, 2009. For the third quarter of 2009, the Company reported a net loss of $6.4 million, compared with a...
LAKE SUCCESS, N.Y., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Aceto Corporation (Nasdaq:ACET), a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of chemically derived pharmaceuticals, nutraceuticals, specialty chemicals and crop protection products, today announced results of operations for its fiscal 2010 first quarter ended September 30, 2009.
CLEVELAND, Nov. 5, 2009 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the quarter ended September 30, 2009. Third Quarter Highlights Include:
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today reported financial results for its second quarter of fiscal 2010, which ended on September 30, 2009.
BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today reported its consolidated financial results for the quarter and nine months ended September 30, 2009.
ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) announced today its financial results for the third quarter and nine months ended September 30, 2009.
ANN ARBOR, Mich., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today reported financial results and operational updates for the first fiscal quarter ended September 30, 2009. Aastrom continues to operate in a capital-efficient manner while advancing its cardiovascular clinical...
FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its financial results as of and for the three and nine months ended September 30, 2009. For the three months ended September 30, 2009, the Company reported a net loss of $7.9 million, or $0.36 per diluted share, compared to a net loss of $18.0 million, or $0.97 per diluted share, for the same period in 2...
COLUMBIA, Md.--(BUSINESS WIRE)--Celsion Corporation (NASDAQ:CLSN), a late stage clinical oncology development company that is leveraging its heat activated liposomal technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced that it will hold a conference call to discuss third quarter 2009 results at 11:00 a.m. Eastern Time on Tuesday, November ...
HAMBURG, Germany, Nov. 6, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (Nasdaq:EVTC) will report its financial results for the third quarter of 2009 on Thursday, 12 November 2009.
FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc.s ("GTC", NASDAQ: GTCB) total net loss for the third quarter ended September 27, 2009 was $5.1 million, or $0.48 per share, compared with $6.1 million, or $0.59 per share, in the third quarter of 2008. The total net loss for the first nine months of 2009 was $26.2 million, or $2.51 per share, compared to $16.5 million, or $1.71 per share...
SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the three and nine months ended September 30, 2009.
MORRIS PLAINS, N.J., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the first quarter ended September 30, 2009. The Company also highlighted recent key developments and planned activities for its clinical pipeline.
BOTHELL, Wash.--(BUSINESS WIRE)--Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced financial results for the third quarter ended September 30, 2009.
ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX), today announced its financial results for the third quarter ended September 30, 2009. The Company held cash, cash equivalents and short-term investments of $21.1 million at September 30, 2009, as compared to $33.1 million at December 31, 2008.
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (the Company or Ligand) today announced financial results for the three and nine months ended September 30, 2009 and provided a business update.
EAST MILLSTONE, N.J.--(BUSINESS WIRE)--Life Sciences Research, Inc. (NYSE Arca: LSR) announced today financial results for the three and nine months ended September 30, 2009.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, today announced financial results for the quarter ended September 30, 2009.
ROCKVILLE, Md., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its third quarter financial results for the quarter ended September 26, 2009. The Company reported a net loss from continuing operations of $7.0 million, or $0.14 per share, compared to a net loss of $4.6 million, or $0.09 per share, for the period ended September 27, 2008.
BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (NASDAQ: NRGN), a drug development company historically focused on drugs for psychiatric and neurological disorders, today announced financial and operating results for the quarter ended September 30, 2009. The Company also announced its analysis of results from a previously suspended Phase 2 study of aplindore in Restless Legs Syndrome (RLS) and...
IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced the date and time for its third quarter 2009 corporate update and pipeline review conference call.
SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the third quarter...
REDWOOD CITY, Calif., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the third quarter ended September 30, 2009.
WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics, today reported its financial results for the third quarter ended September 30, 2009.
SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN) today reported improved financial results for the third quarter ended September 30, 2009. The companys net loss for the quarter declined substantially to $11.4 million, or $0.17 per share, from $28.8 million, or $0.42 per share, for the third quarter of 2008. Revenues for the third quarter of 2009 increased by 131% compared to the third quarter...
DUBLIN--(BUSINESS WIRE)--Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of John F. Thero as the Companys Chief Financial Officer. In this role, Mr. Thero will have broad responsibility for financial and administrative matters of the Company and be actively involved in corporate development and other strategic and operational matters. He will report directly to Dr. Declan Doogan...
LEXINGTON, Mass.--(BUSINESS WIRE)--TARIS Biomedical, a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, announced today the appointment of Julie Lekstrom Himes, M.D. to join TARIS in the position of Chief Medical Officer and Senior Vice President for Clinical Development. Dr. Himes has broad clinical research and operations experience within the...
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has appointed Bernard R. Tyrrell as the Companys Senior Vice President, Sales and Marketing, a newly created position. Mr. Tyrrell joins EpiCept with a wealth of experience in pharmaceutical marketing and business development, both in the U.S. and internationally. Most...
CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that Tim Rothwell, former Chairman of Sanofi-aventis U.S., has been appointed to the Companys Board of Directors effective immediately. Mr. Rothwells appointment fills the vacancy created by Franklin Berger, who recently resigned from the Board in order to focus more time on certain other business endeavors...
REDMOND, Wash.--(BUSINESS WIRE)--Visitors to the newly branded and redesigned website of the Washington Biotechnology & Biomedical Association (WBBA) to be featured at the WBBAs Annual Meeting today will get free, timely, Washington state-focused biotech and medtech news through its Economic Issues in WA Healthcare Breaking News feature. This new feature, powered by MedIntelliBase Intelligence...
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Thirty-two Purdue University faculty and staff will be recognized at the Purdue Research Foundation's annual Inventors Recognition Dinner on Thursday (Nov. 5).
WALTHAM, Mass.--(BUSINESS WIRE)--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced the Mass Technology Leadership Council, Inc. named Phase Forward Private Sector Company of the Year at the 2009 Mass Technology Leadership Awards in Boston last night. Honoring Massachusetts companies and individuals who best exemplify leadership...
BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) today announced that William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, is scheduled to speak at the Credit Suisse 18th Annual Healthcare Conference in Phoenix AZ. LabCorps presentation is planned for Friday, November 13, 2009 at 9:30 a.m. (Mountain Standard Time).
BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that its presentation at the 2009 Annual Credit Suisse Health Care Conference will be webcast and may be accessed at www.sucampo.com.
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (Nasdaq: BIOS) today announced that it will present at the 18th Annual Credit Suisse Healthcare Conference to be held November 11-13, 2009 at the Arizona Biltmore Resort & Spa in Phoenix, Arizona.
BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG) today announced plans to provide a live webcast of its presentation scheduled for Thursday, November 12, 2009, at 9:00 am Mountain Standard Time (11:00 am Eastern Standard Time), at the Credit Suisse 2009 Healthcare Conference at the Arizona Biltmore Hotel in Phoenix, Arizona. The presentation may include a discussion of the Company...
Philly.com -- Johnson & Johnson said today that it was closing research & development facilities in Radnor and Chesterbrook and consolidating those operations at the company's Spring House site.